Videos

Triggers that may lead a hematologist/oncologist to consider reinstituting therapy for a patient with transplant-ineligible multiple myeloma (MM) who received prior therapy but was not treated to progression.

Drs Liliana Bustamante and Richard Kim review “Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases,” by Loupakis F, et al.

A review of data from the eNRGy1 global registry study, with deference to the efficacy of current therapies and clinicopathologic features.

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk about the important role that patient support networks play for those with cancer and the challenge of separating patients from their loved ones during the COVID-19 pandemic.

A panel of experts reflects on appropriate actions to take after a patient achieves adequate response to therapy for transplant-ineligible multiple myeloma.

Shared insight on how best to assess a patient’s response to therapy for transplant-ineligible multiple myeloma.

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about how the COVID-19 pandemic impacted the care of multiple myeloma at the Oslo Myeloma Center .

Ravi A. Madan, MD, discusses the potential impact of docetaxel, abiraterone acetate, androgen deprivation therapy, and radiotherapy on patients with metastatic castration-sensitive prostate cancer.

The rationale behind treating patients with newly diagnosed transplant-ineligible multiple myeloma (MM) until disease progression rather than stopping therapy at a designated point in time.

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about how he would like to see the OCEAN trial and Melflufen progress for relapsed/refractory multiple myeloma.

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about the most common adverse effects experienced from the quadruplet drug treatment for patients with multiple myeloma.

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to discuss the differences in safety profiles between melflufen/dexamethasone and pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Take-home points from the MAIA trial of daratumumab plus lenalidomide and dexamethasone as therapy for patients with newly diagnosed transplant-ineligible multiple myeloma, and recommendations regarding maintenance therapy following the use of a triplet regimen.

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about importance of subgroups when administering melflufen and dexamethasone to patients with relapsed/refractory multiple myeloma.

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about the most important data from the phase 2 MASTER trial in newly diagnosed multiple myeloma.

Panelists elucidate how to determine transplant ineligibility and the goals of therapy while managing a patient with multiple myeloma.

Shared insight on the difficulties of transplant-ineligible newly diagnosed multiple myeloma and how to optimally approach treatment.

Solange Peters, MD, PhD, detailed several important abstracts from the Presidential Symposia at the 2021 ESMO Congress she believes will be practice changing.

Scenarios for which a doublet regimen may be recommended over a triplet therapy for the management of newly diagnosed transplant-ineligible multiple myeloma.

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk about key findings observed when utilizing cabazitaxel vs a second androgen receptor targeted agent in metastatic castration-resistant prostate cancer.

Marshall Posner, MD, detailed the potential for personalized mRNA vaccines to treat patients with various different tumors and what information is still needed.

ESMO’s president, Solange Peters, MD, PhD, discussed a handful of key abstracts presented during the 3 Presidential Symposia sessions at the 2021 ESMO Congress.

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about COVID-19 and immediate changes that took place during the pandemic.

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about the decision to start the phase 2 MASTER trial for multiple myeloma.

A panel of hematologist-oncologists comment on how they would treat a 74-year-old patient with newly diagnosed transplant-ineligible multiple myeloma.

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about future indications of mobocertinib.

CancerNetwork® sat down with David O’Malley, MD, at the 2021 European Society for Medical Oncology to talk about the OReO trial and how these findings impact what’s already known about PARP inhibitors for the treatment of ovarian cancer.

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to discuss key data that read out from the OCEAN trial for relapsed/refractory multiple myeloma.

CancerNetwork® spoke with Michael Schweizer, MD, at the 2021 ESMO Congress about his research into the combination of olaparib plus bipolar androgen therapy for patients with castration-resistant prostate cancer.

Recommended next steps regarding treatment for patients with transplant-ineligible multiple myeloma based on prior responses to therapy.